NCT02142868No Longer Available不适用
AN EXPANDED ACCESS STUDY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE AS TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE ADVANCED BREAST CANCER FOR WHOM LETROZOLE THERAPY IS DEEMED APPROPRIATE
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- Pfizer
- 试验地点
- 45
研究概览
简要总结
To provide access to palbociclib to post-menopausal women with HR-positive, HER2-negative advanced breast cancer who are deemed appropriate for letrozole therapy (Canada: first-line patients only).
详细描述
This study is currently available in Canada only.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Post-menopausal women 18 years of age or above with proven diagnosis of advanced adenocarcinoma of the breast (locoregionally recurrent or metastatic disease)
- •ER-positive and/or PR-positive tumor based on local laboratory results
- •HER2-negative tumor based on local laboratory results
- •Patients must be appropriate candidates for letrozole therapy (Canada: first-line patients only)
排除标准
- •Patients who have previously participated in a palbociclib trial or who have received prior treatment with any CDK inhibitor
研究者
研究点 (45)
Loading locations...
相似试验
Unknown
2 期
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBCMetastatic Breast CancerNCT02592746Samsung Medical Center182
已完成
4 期
Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast CancerBreast CancerNCT02679755Pfizer252
Unknown
3 期
Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)Chronic Hepatitis CMenopauseNCT01457937University of Modena and Reggio Emilia240
已完成
2 期
Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABCBreast Neoplasm FemaleNCT05969184Peking University Cancer Hospital & Institute94
已完成
2 期
Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)Breast Cancer FemaleNCT03065621Jules Bordet Institute100